In the specification:

Please delete the paragraph at page 3, lines 5-25 and substitute the following therefore:

wherein

W is H or C_1-C_4 branched alkyl or straight chained alkyl;

X is CH_2, NH, or NCH_3; n is 1 or 2;

Y is O or CH_2; m is 0 or 1, provided that if X is CH_2, n is 1 and m is 0, then R^1 is not CH_2CH_3;

Z is 0; p is 0 or 1;

R^1 is H, a C_1-C_7 straight chain alkyl, a C_3-C_7 branched chain alkyl, a C_1-C_4 haloalkyl, a C_3-C_7 cycloalkyl, an aryl, a heteroaryl, an aralkyl, or a heteroalkyl;

R^2 is phenyl, 2-halophenyl, or 2-pyridyl,

R^3 is H, Cl, Br, F, I, CF_3 or NO_2;

(1) R^4 is H, C_1-C_4 alkyl, or dialkylaminoalkyl and R^5 and R^6 together represent a single oxygen or S atom which is linked to the diazepine ring by a double bond and p is zero or 1 (as depicted in formula Ia); or (2) R^4 and R^5 together form a double bond in the diazepine ring and R^6 represents the group NHR^7 wherein R^7 is H, C_{1-4} alkyl, C_{1-4} hydroxylalkyl, pyridylmethyl, pyridyl ethyl, imidazolylethyl, benzyl, or benzyl mono or disubstituted independently with halogen substituents, C_{1-4}alkylpyridyl or C_{1-4} alkylimidazolyl and p is zero (as depicted in formula Ib); or (3) R^4, and R^6 form the group $-CR^8$=U-V=W wherein R^8 is hydrogen, C_{1-4} alkyl, or C_{1-3} hydroxyalkyl, U is N or CR^9 wherein R^9 is H, C_{1-4}alkyl, C_{1-3}hydroxyalkyl or C_{1-4}alkoxy- C_{1-4}alkyl, V is N or CH and p is zero (as depicted in formula Ic);

or pharmaceutically acceptable salts or solvates thereof.